Literature DB >> 32327962

Hypothesized and found mechanisms for potentiation of bradykinin actions.

Sylvia Mueller1, Inge Paegelow2, Siegmund Reissmann1,2.   

Abstract

Potentiation of hormone actions can occur by different mechanisms, including inhibition of degrading enzymes, interaction with the hormone receptor leading to stabilization of bioactive conformation or leading to receptor homo- and hetero-oligomerization, receptor phosphorylation and dephosphorylation or can occur by directly influencing the signal transduction and ion channels. In this review the potentiation of bradykinin actions in different systems by certain compounds will be reviewed. Despite many long years of experimental research and investigation the mechanisms of potentiating action remain not fully understood. One of the most contradictory findings are the distinct differences between the inhibition of the angiotensin I-converting enzyme and the potentiation of the bradykinin induced smooth muscle reaction. Contradictory findings and hypothesized mechanisms in the literature are discussed in this review and in some cases compared to own results. Investigation of potentiating actions was extended from hypotension, smooth muscle reaction and cellular actions to activation of immunocompetent cells. In our opinion the potentiation of bradykinin action can occur by different mechanisms, depending on the system and the applied potentiating factor used.
Copyright © 2006 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  Angiotensin I‐converting enzyme; Bradykinin B1 and B2 receptors; Crosstalk; Polymorphonuclear leukocytes; Potentiation

Year:  2006        PMID: 32327962      PMCID: PMC7169587          DOI: 10.1002/sita.200500061

Source DB:  PubMed          Journal:  Signal Transduct        ISSN: 1615-4053


  112 in total

1.  ACE inhibitor potentiation of bradykinin-induced venoconstriction.

Authors:  M Hecker; A Blaukat; A T Bara; W Müller-Esterl; R Busse
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

2.  Primary structure and biological activity of bradykinin potentiating peptides from Bothrops insularis snake venom.

Authors:  A C Cintra; C A Vieira; J R Giglio
Journal:  J Protein Chem       Date:  1990-04

3.  N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE.

Authors:  P A Deddish; B Marcic; H L Jackman; H Z Wang; R A Skidgel; E G Erdös
Journal:  Hypertension       Date:  1998-04       Impact factor: 10.190

4.  A new class of angiotensin-converting enzyme inhibitors.

Authors:  A A Patchett; E Harris; E W Tristram; M J Wyvratt; M T Wu; D Taub; E R Peterson; T J Ikeler; J ten Broeke; L G Payne; D L Ondeyka; E D Thorsett; W J Greenlee; N S Lohr; R D Hoffsommer; H Joshua; W V Ruyle; J W Rothrock; S D Aster; A L Maycock; F M Robinson; R Hirschmann; C S Sweet; E H Ulm; D M Gross; T C Vassil; C A Stone
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

5.  Synthesis of novel angiotensin converting enzyme inhibitor quinapril and related compounds. A divergence of structure-activity relationships for non-sulfhydryl and sulfhydryl types.

Authors:  S Klutchko; C J Blankley; R W Fleming; J M Hinkley; A E Werner; I Nordin; A Holmes; M L Hoefle; D M Cohen; A D Essenburg
Journal:  J Med Chem       Date:  1986-10       Impact factor: 7.446

6.  Activation of G proteins by neuropeptide Y and gamma-aminobutyric acid(B) receptor agonists in rat cerebral cortical membranes through distinct modes of action.

Authors:  Y Odagaki; N Nishi; S Nakagawa; T Koyama
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

7.  Insulin enhances the bradykinin response in L8 rat skeletal myoblasts.

Authors:  A Kudoh; G J Dietze; S F Rabito
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

8.  Synthesis and biological activities of new side chain and backbone cyclic bradykinin analogues.

Authors:  C Schumann; L Seyfarth; G Greiner; I Paegelow; S Reissmann
Journal:  J Pept Res       Date:  2002-08

9.  Analysis of structural requirements for TRH-potentiating peptide receptor binding by analogue design.

Authors:  A Ladram; J J Montagne; M Bulant; P Nicolas
Journal:  Peptides       Date:  1994       Impact factor: 3.750

10.  The two homologous domains of human angiotensin I-converting enzyme are both catalytically active.

Authors:  L Wei; F Alhenc-Gelas; P Corvol; E Clauser
Journal:  J Biol Chem       Date:  1991-05-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.